The managing partner of 5AM Ventures, Dr. Scott M. Rocklage, has spent more than three decades in healthcare management. Dr. Rocklage graduated from UC, Berkley with a B.S. in Chemistry and then attended the Massachusetts Institute of Technology where he earned a PhD in Chemistry. He spent some of his time at MIT doing research in 2005 Nobel Prize winner Richard R. Schrock’s laboratory.
Since then, Dr. Rocklage has helped the drugs Omniscan, Teslascan and Cubicin gain FDA approval and got clinical trials for six other drug candidates. In addition to having his work appear in over 100 peer-reviewed publication, he’s the inventor or co-inventor of dozens of U.S. patents.
During Dr. Scott Rocklage’s long and illustrious career, he has held leadership positions and board membership in a wide array of biotech companies. They include Cubist Pharmaceuticals, Nycomed Salutar, Relypsa, Novira, Ilypsa, Miikana and Semprus.
He also worked in research and development with Salutar and Catalytica. Currently, Dr. Rocklage is on the directorial boards of Rennovia, Kinestral, Cidara, Epirus and Pulmatrix. In 2003, he joined Menlo Park, California based life science venture capital firm 5AM Ventures as a venture partner. He became a managing partner the next year. Read more: Scott Rocklage | Ideamesch and Scott Rocklage | Crunchbase
At 5AM Ventures Dr. Rocklage works with physicians, scientists and business executives on early stage company formation. He helps them transform their ideas into medicines that can potentially be used to treat a wide range of medical conditions. He also collaborates with 5AM Ventures’ portfolio management team.
Dr. Rocklage is very excited about the explosive growth in the development of targeted treatments for specific mutations or genotypes that allow medical professionals to create new and better was to treat cancer. These developments extend, improve and save lives.
Some of the most important reasons for Dr. Rocklage’s productivity and success are his focus on organization, prioritization, time management and calendaring. Another thing that has helped is he is not afraid of measured risk-taking.
He feels that he does his very best work when he controls his own time and future through entrepreneurship rather than getting a job with an established Fortune 500 company.
Learn more about Scott Rocklage: